DexCom, Inc. $DXCM Shares Bought by Sterling Capital Management LLC

Sterling Capital Management LLC increased its position in DexCom, Inc. (NASDAQ:DXCM) by 36.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 350,140 shares of the medical device company’s stock after acquiring an additional 93,526 shares during the period. Sterling Capital Management LLC owned approximately 0.09% of DexCom worth $30,564,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Andra AP fonden bought a new stake in shares of DexCom during the second quarter valued at approximately $26,000. Brooktree Capital Management increased its position in DexCom by 88.3% in the 2nd quarter. Brooktree Capital Management now owns 29,245 shares of the medical device company’s stock valued at $2,553,000 after acquiring an additional 13,713 shares during the period. Resona Asset Management Co. Ltd. raised its stake in DexCom by 8.8% during the 2nd quarter. Resona Asset Management Co. Ltd. now owns 137,292 shares of the medical device company’s stock valued at $11,962,000 after acquiring an additional 11,139 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new position in DexCom during the 2nd quarter worth $70,000. Finally, First Horizon Advisors Inc. grew its stake in shares of DexCom by 44.2% in the second quarter. First Horizon Advisors Inc. now owns 2,281 shares of the medical device company’s stock worth $199,000 after purchasing an additional 699 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Robert W. Baird set a $82.00 price objective on shares of DexCom in a research note on Friday, October 31st. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 10th. Stifel Nicolaus started coverage on DexCom in a research report on Tuesday, October 21st. They set a “buy” rating and a $85.00 price target on the stock. Royal Bank Of Canada lowered their target price on DexCom from $100.00 to $85.00 and set an “outperform” rating on the stock in a report on Friday, October 31st. Finally, Canaccord Genuity Group set a $99.00 price objective on shares of DexCom and gave the company a “buy” rating in a research report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $89.33.

Insiders Place Their Bets

In other news, EVP Michael Jon Brown sold 500 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the sale, the executive vice president directly owned 94,102 shares of the company’s stock, valued at $7,555,449.58. This represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kyle Malady sold 667 shares of the business’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the transaction, the director directly owned 22,667 shares in the company, valued at $1,832,853.62. The trade was a 2.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 5,383 shares of company stock valued at $434,274. 0.32% of the stock is owned by insiders.

DexCom Trading Down 2.1%

DexCom stock opened at $58.02 on Friday. DexCom, Inc. has a 52 week low of $56.44 and a 52 week high of $93.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The firm has a market capitalization of $22.63 billion, a price-to-earnings ratio of 40.29, a P/E/G ratio of 1.43 and a beta of 1.40. The company has a 50 day moving average price of $69.65 and a 200 day moving average price of $77.65.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. The company had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.45 earnings per share. DexCom has set its FY 2025 guidance at EPS. Research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.